Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

The role of the potassium channel gene KCNK2 in major depressive disorder.

Congiu C, Minelli A, Bonvicini C, Bortolomasi M, Sartori R, Maj C, Scassellati C, Maina G, Trabucchi L, Segala M, Gennarelli M.

Psychiatry Res. 2015 Feb 28;225(3):489-92. doi: 10.1016/j.psychres.2014.11.061. Epub 2014 Dec 9.

2.

Personalized medicine in Alzheimer's disease and depression.

Souslova T, Marple TC, Spiekerman AM, Mohammad AA.

Contemp Clin Trials. 2013 Nov;36(2):616-23. doi: 10.1016/j.cct.2013.06.012. Epub 2013 Jun 29. Review.

PMID:
23816492
3.

Pharmacogenetics studies in STAR*D: strengths, limitations, and results.

Laje G, Perlis RH, Rush AJ, McMahon FJ.

Psychiatr Serv. 2009 Nov;60(11):1446-57. doi: 10.1176/appi.ps.60.11.1446.

4.

Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment.

Liou YJ, Chen TJ, Tsai SJ, Yu YW, Cheng CY, Hong CJ.

Pharmacogenet Genomics. 2009 Oct;19(10):735-41. doi: 10.1097/FPC.0b013e32832cbe61.

PMID:
19741570
5.

Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study.

Perlis RH, Moorjani P, Fagerness J, Purcell S, Trivedi MH, Fava M, Rush AJ, Smoller JW.

Neuropsychopharmacology. 2008 Nov;33(12):2810-9. doi: 10.1038/npp.2008.6. Epub 2008 Feb 20.

6.

Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype.

Heurteaux C, Lucas G, Guy N, El Yacoubi M, Th├╝mmler S, Peng XD, Noble F, Blondeau N, Widmann C, Borsotto M, Gobbi G, Vaugeois JM, Debonnel G, Lazdunski M.

Nat Neurosci. 2006 Sep;9(9):1134-41. Epub 2006 Aug 13.

PMID:
16906152

Supplemental Content

Loading ...
Support Center